24
GlaxoSmithKline Pharmaceuticals
CEO |
Dr Hasit Joshipura
|
|
Business |
Sales of vaccines |
Start-up Year |
2001 |
Biotech Revenue |
Rs 123.34 crore |
Address |
Dr Annie Besant Road, Worli, Mumbai-40030
|
Tel |
+91-22-24959205 |
Fax |
+91-22-24914863 |
Website |
www.gsk-india.com |
GlaxoSmithKline (GSK) Pharmaceutical recorded a total biotech sales
revenue of Rs 123.34 crore in the fiscal year ended March 31, 2010.
Vaccines has been a key focus area for GSK in the Indian market and it
holds 51 percent market share in the Indian vaccine market. Andrew
Witty, Global CEO, GSK on his visit to India in in March 2010, said,
“India itself is a key priority for GSK itself. This is one of
the great emerging economies of the world and will be a
great economic story in the next 50 years.” Witty had specifically
flown down to Nashik in order to dedicate the new albendazole
manufacturing production facility, to the WHO global program to
eliminate Lymphatic Filariasis (LF). He has pinned hopes that this
would be the starting point and probably in the future he would hope to
see more such manufacturing facilities here in India. This new
facility, built with an investment of Rs 15 million, will deliver an
additional 300 million treatments of albendazole per year. It will
double GSK’s annual manufacturing capacity for the LF program.
25
Intervet India
MD |
Dr Lino Componovo |
|
Business |
R&D and
manufacturing of
veterinary biologicals
|
Start-up Year |
1997 |
Biotech Revenue |
Rs 121.66 crore |
Address |
Intervet House, 33, Pune-Nagar Road, (Behind
Eden Gardens), Pune - 411 014
|
Tel |
+91-20-66050400-01 |
Fax |
+91-20-66050410 |
Website |
www.intervet.co.in |
Intervet India’s sales from biotech products stood at Rs 121.66
crore. Intervet India offers a range of products consisting of
biologicals, therapeutics, productive hormones to the farming community
in the country. Intervet India, is a 100 percent subsidiary of Intervet
International with its headquarters at Boxmeer, Netherlands.
Intervet India has a factory producing biologicals, specially FMD
vaccine located at Wagholi near Pune. As of the latest news, Intervet
has stopped manufacturing poultry vaccines in India and now imports
vaccines and markets them in the country. The distribution of
Intervet’s products takes place through a network of agents ensuring
cold chain maintenance and subsequent distribution through 900
distributors. Intervet India had also entered into a partnership with
an NGO, BAIF Development Research Foundation to improve disease
management and productivity at rural level, as well as promoting
livestock healthcare awareness. The partnership also offers
self-employed farmers in remote villages to access to vital veterinary
products at a fair price.
26
Advanced Enzyme Technologies
CEO |
Dr CL Rathi |
|
Business |
R&D, manufacturing and marketing of enzymes
|
Start-up Year |
1989 |
Biotech Revenue |
Rs 121 crore |
Address |
Sun Magnetica, A Wing, 5th floor, LIC Service Rd,
Louiswadi, Thane (W)- 400 604
|
Tel |
+91-22-41703200 |
Fax |
+91-22-25835159 |
Website |
www.enzyme.com |
Advanced Enzymes Technologies Limited (AETL) registered a total sales
revenue of Rs 121 crore for the fiscal 2009-2010 as against Rs 88.6
crore in 2008-2009. AETL is a research driven company having global
leadership in manufacturing enzymes and probiotics. AETL operates
in four key verticals: human healthcare, animal healthcare, food
processing and industrial processing. For each of these verticals
they have created subsidiaries which focus exclusively on delivering
solutions to the industries that operate within that vertical. Exports
constitutes a major part of the sales for AETL. The US has a major
geographical share for AETL’s exports which is around 50-60 percent in
totality. The company also spends around 10-12 percent of their total
turnover on R&D. Catering to a worldwide market in geographies like
Europe, America, China and India, AETL, specializes in providing
customized, eco-safe solutions across various industries.
AETL has multi-disciplinary R&D team consisting of microbiologists,
biochemists, chemical engineers, food technologists, and
biotechnologists with several years of experience with enzyme
technology.